MIRM Mirum Pharmaceuticals Inc

Price (delayed)

$89.32

Market cap

$5.8B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$14.55

Enterprise value

$6.23B

?
Relative Growth: Rel. Growth: 35
Relative Strength: Rel. Strength: 45
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 13

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, ...

Highlights
The company's gross profit rose by 49% YoY and by 9% QoQ
The revenue has grown by 44% YoY and by 9% from the previous quarter
The quick ratio is up by 38% since the previous quarter but it has declined by 7% year-on-year
The company's debt has surged by 140% YoY and by 137% QoQ
Mirum Pharmaceuticals's equity has plunged by 104% from the previous quarter and by 104% YoY

Key stats

What are the main financial stats of MIRM

MIRM stock price

How has the Mirum Pharmaceuticals stock price performed over time
Intraday
-2.27%
1 week
-8.27%
1 month
-7.26%
1 year
21.33%
YTD
13.08%
QTD
-23.7%

Financial performance

How have Mirum Pharmaceuticals's revenue and profit performed over time
Revenue
$618.07M
Gross profit
$505.11M
Operating income
-$833.97M
Net income
-$860.21M
Gross margin
81.7%
Net margin
-139.2%
The company's gross profit rose by 49% YoY and by 9% QoQ
The revenue has grown by 44% YoY and by 9% from the previous quarter
The net income has contracted by 8% from the previous quarter
Mirum Pharmaceuticals's operating income has decreased by 4.7% QoQ

Price vs fundamentals

How does MIRM's price correlate with its fundamentals

Growth

What is Mirum Pharmaceuticals's growth rate over time

Valuation

What is Mirum Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
9.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.08
The EPS has contracted by 7% from the previous quarter
Mirum Pharmaceuticals's equity has plunged by 104% from the previous quarter and by 104% YoY
The revenue has grown by 44% YoY and by 9% from the previous quarter
MIRM's price to sales (P/S) is 18% lower than its 5-year quarterly average of 11.4

Efficiency

How efficient is Mirum Pharmaceuticals business performance
The ROE has decreased by 42% QoQ
The ROIC has grown by 20% from the previous quarter
Mirum Pharmaceuticals's return on assets has increased by 2% QoQ

Dividends

What is MIRM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MIRM.

Financial health

How did Mirum Pharmaceuticals financials performed over time
The total liabilities has soared by 124% YoY and by 63% from the previous quarter
MIRM's total assets is up by 44% YoY and by 17% QoQ
The company's debt has surged by 140% YoY and by 137% QoQ
Mirum Pharmaceuticals's equity has plunged by 104% from the previous quarter and by 104% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.